European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast CancerBusiness Wire • 01/03/23
Gilead and EVOQ Therapeutics Announce Collaboration to Advance ImmunotherapiesBusiness Wire • 01/03/23
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce TherapeuticsBusiness Wire • 12/27/22
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell LymphomaBusiness Wire • 12/22/22
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIVBusiness Wire • 12/22/22
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectationsProactive Investors • 12/20/22
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drugMarket Watch • 12/20/22